Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Comer

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Journal of Infectious Diseases|May 5, 2023
Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman PrimatesAbhishek N Prasad, Karla A Fenton, Krystle N Agans, et al.
Viruses|October 27, 2022
Natural History of Marburg Virus Infection to Support Medical Countermeasure DevelopmentJason E Comer, Trevor Brasel, Shane Massey, et al.
Viruses|July 27, 2024
Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus DiseaseDylan M Johnson, Terry Juelich, Lihong Zhang, et al.
Scientific Reports|March 14, 2023
Natural history of nonhuman primates after conjunctival exposure to Ebola virusRobert W Cross, Abhishek N Prasad, Courtney B Woolsey, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthraxNutan Mytle, Robert J Hopkins, Nina V Malkevich, et al.
Infection and Immunity|April 25, 2007
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit modelJohnny W Peterson, Jason E Comer, Wallace B Baze, et al.
Plos One|July 2, 2021
Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus diseaseNancy A Niemuth, Dawn Fallacara, Cheryl A Triplett, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Journal of Infectious Diseases|May 5, 2023
Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman PrimatesAbhishek N Prasad, Karla A Fenton, Krystle N Agans, et al.
Viruses|October 27, 2022
Natural History of Marburg Virus Infection to Support Medical Countermeasure DevelopmentJason E Comer, Trevor Brasel, Shane Massey, et al.
Viruses|July 27, 2024
Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus DiseaseDylan M Johnson, Terry Juelich, Lihong Zhang, et al.
Scientific Reports|March 14, 2023
Natural history of nonhuman primates after conjunctival exposure to Ebola virusRobert W Cross, Abhishek N Prasad, Courtney B Woolsey, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthraxNutan Mytle, Robert J Hopkins, Nina V Malkevich, et al.
Infection and Immunity|April 25, 2007
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit modelJohnny W Peterson, Jason E Comer, Wallace B Baze, et al.
Plos One|July 2, 2021
Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus diseaseNancy A Niemuth, Dawn Fallacara, Cheryl A Triplett, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 5